Silo Pharma (SILO) said Wednesday the US Patent and Trademark Office issued a notification for its "Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females" application.
The patent reinforces protection for its lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder, the company said.
"This new patent further supports our collaborative research with Columbia University and expands coverage for SPC-15," said Chief Executive Officer Eric Weisblum.
Price: 1.36, Change: -0.03, Percent Change: -2.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。